ChemoCentryx Inc  

(Public, NASDAQ:CCXI)   Watch this stock  
Find more results for CCXI
8.83
+0.08 (0.91%)
Jan 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.50 - 9.00
52 week 4.06 - 9.00
Open 8.71
Vol / Avg. 0.00/636,237.00
Mkt cap 376.25M
P/E     -
Div/yield     -
EPS -0.97
Shares 43.34M
Beta     -
Inst. own 69%
Jan 14, 2015
ChemoCentryx Inc at JPMorgan Healthcare Conference
Dec 12, 2014
ChemoCentryx Inc Conference Call to Discuss Top-Line Phase II Results in Patients With Diabetic Nephropathy With CCX140 - Webcast
Nov 20, 2014
ChemoCentryx Inc at Goldman Sachs US Emerging / SMID Cap Growth Conference
Nov 19, 2014
ChemoCentryx Inc at Stifel Healthcare Conference
Nov 5, 2014
Q3 2014 ChemoCentryx Inc Earnings Call
Nov 5, 2014
Q3 2014 ChemoCentryx Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -638.17%
Operating margin - -645.46%
EBITD margin - -635.96%
Return on average assets -33.45% -28.15%
Return on average equity -35.69% -30.25%
Employees 60 -
CDP Score - -

Address

850 MAUDE AVENUE
MOUNTAIN VIEW, CA 94043
United States - Map
+1-650-2102900 (Phone)
+1-650-2102910 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company focuses on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules including chemokine ligands and their associated receptors and chemo-attractant receptors. The Company has five drug candidates in clinical development, which include CCX168, CCX140, CCX872, Traficet-EN and CCX507. CCX168 targets the chemo-attractant C5a receptor, which binds to a fragment of the complement protein known as C5. CCX140 targets the chemokine receptor known as CCR2. CCX872 is the Company�s second generation CCR2 inhibitor for the treatment of metabolic diseases, such as atherosclerosis and cardiovascular disease. Traficet-EN is intended to control the inflammatory response by targeting the chemokine receptor known as CCR9. CCX507 works in the area of CCR9 inhibitors.

Officers and directors

Thomas J. Schall Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Susan M. Kanaya Chief Financial Officer, Senior Vice President - Finance, Secretary
Age: 51
Bio & Compensation  - Reuters
Petrus J. Bekker M.D., Ph.D. Senior Vice President - Clinical and Medical Affairs
Age: 53
Bio & Compensation  - Reuters
Israel F. Charo M.D., Ph.D. Senior Vice President - Research
Bio & Compensation  - Reuters
Markus J. Cappel Ph.D. Chief Business Officer, Treasurer
Age: 53
Bio & Compensation  - Reuters
Roger C. Lucas Ph.D. Lead Independent Director
Age: 71
Bio & Compensation  - Reuters
Joseph M. Feczko M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Ira Klein M.D. Independent Director
Age: 51
Bio & Compensation  - Reuters
Geoffrey M. Parker Independent Director
Age: 49
Bio & Compensation  - Reuters
James L. Tyree Independent Director
Age: 61
Bio & Compensation  - Reuters